ImCheck Therapeutics will present updated Phase I/II EVICTION trial data showing high complete remission rates when ICT01 is combined with azacitidine and venetoclax in newly diagnosed AML patients.
Precision medicine deals reached $97.39 million in 2023, with cell therapies projected to generate over $52 billion by 2029, marking significant growth in personalized treatment approaches.
The FDA granted Fast Track designation to ICT01 plus azacitidine and venetoclax for acute myeloid leukemia (AML) treatment in patients unfit for standard induction chemotherapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.